Format

Send to

Choose Destination
Emerg Infect Dis. 2005 Jun;11(6):802-7.

Hidden epidemic of macrolide-resistant pneumococci.

Author information

1
Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia 30322, USA. keith.klugman@emory.edu

Abstract

Community-acquired respiratory tract infections (RTIs) account for a substantial proportion of outpatient antimicrobial drug prescriptions worldwide. Concern over the emergence of multidrug resistance in pneumococci has largely been focused on penicillin-resistant Streptococcus pneumoniae. Macrolide antimicrobial drugs have been widely used to empirically treat community-acquired RTIs because of their efficacy in treating both common and atypical respiratory pathogens, including S. pneumoniae. However, increased macrolide use has been associated with a global increase in pneumococcal resistance, which is leading to concern over the continued clinical efficacy of the macrolides to treat community-acquired RTIs. We provide an overview of macrolide-resistant S. pneumoniae and assess the impact of this resistance on the empiric treatment of community-acquired RTIs.

PMID:
15963272
PMCID:
PMC3367596
DOI:
10.3201/eid1106.050147
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for CDC-NCEZID Icon for PubMed Central
Loading ...
Support Center